Evidence map›Paper›PMID 22378286›Full record

ArticleEuropean journal of human genetics : EJHG2012

Spontaneous disclosure of BRCA1/2 genetic test results to employers: a French prospective study.

François Eisinger, Roxane Fabre, Christine Lasset, Dominique Stoppa-Lyonnet, Claire Julian-Reynier, Catherine Nogues

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03667417 (Genetic Predisposition to Breast and Ovarian Cancer), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03667417 recruitingnot on this map

Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation

TypeobservationalSponsorInstitut Paoli-CalmettesRan1999 to 2028Enrolled5,000ConditionsBreast Cancers, Ovarian CancersArmsQuestionnaires
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Disclosure of research results: a randomized study on GENEPSO-PS cohort participants.Health expectations : an international journal of public participation in health care and health policy · 2016
    Trial
  2. Article
  3. "Maybe they have found something new" participants' views on returning cohort psychosocial survey results.Health expectations : an international journal of public participation in health care and health policy · 2015
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 1 country.

François EisingerInstitut Paoli-Calmettes, Marseille, France.
Roxane Fabre
Christine Lasset
Dominique Stoppa-Lyonnet
Claire Julian-Reynier
Catherine Nogues
Aix-Marseille Université · FRCentre Léon Bérard · FRHôpital René Huguenin · FRInserm · FRInstitut Curie · FRInstitut Paoli-Calmettes · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to examine the patterns of disclosure of BRCA1/2 genetic test results to employers by unaffected carriers. In a national prospective cohort study on unaffected BRCA1/2 mutation carriers, disclosure to employers was assessed prospectively, using self-administered questionnaires, up to 2 years after their test results were delivered by cancer geneticists. Kaplan-Meier curves and Cox-regression analysis were used to assess the factors associated with time to disclosure to the employer. Mean age of the 146 women BRCA1/2 carriers who were employed when their test results were delivered was 37.1 years (range: 19-57). At the end of the second year of follow-up, 47 of them (32.2%) had disclosed their results to their employers; median time to disclosure was 6 months. Reasons spontaneously expressed were first to inform the employer that medical surveillance/surgery was necessary for cancer risk management although these carriers did not actually have cancer. After multivariate adjustment on age, women with a lower educational level (HRadj=2.00, P=0.026) and those who had undergone prophylactic surgery during the 2 years of follow-up (HRadj=2.18, P=0.019) had disclosed their BRCA status to their employers earlier and more frequently. One-third of the female carriers not affected by breast/ovarian cancer disclosed their BRCA1/2 genetic test results spontaneously to their employers, mainly to inform them that they were disease-free but required medical surveillance or a surgical intervention to reduce the risk of cancer.

Indexed as

Genes, BRCA1Genes, BRCA2AdultAsymptomatic DiseasesBreast NeoplasmsDisclosureEducational StatusFemaleFranceGenetic TestingHeterozygoteHumansKaplan-Meier EstimateMiddle AgedOvarian NeoplasmsProportional Hazards Models

Identifiers

PMID22378286
PMCPMC3421122
OpenAlexW1975505393

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.